Sector News

Would BMS-Celgene control too much of the psoriasis business? FTC wants to find out

March 27, 2019
Life sciences

Turns out shareholders aren’t the only ones who have some issues with Bristol-Myers Squibb’s proposed $74 billion Celgene merger.

The Federal Trade Commission (FTC) is taking a closer look at the companies’ psoriasis drugs, both those on the market and those making their way through the clinic, Celgene said in a regulatory filing (PDF). The agency asked Bristol-Myers and Celgene Monday to hand over additional info and documents about their respective drugs.

Celgene said the companies “will continue to cooperate with the FTC staff in its review of the transactions contemplated by the Merger Agreement.”

Right now, Bristol and Celgene don’t think the review will throw off their deal timeline; they still expect the transaction to wrap in this year’s third quarter. But a potential overlap in psoriasis offerings, as determined by the FTC, could result in castoffs of marketed or pipeline products—a scenario that could hurt the combined company’s prospects as it aims to become a top immunology player.

Celgene sells Otezla, a next-generation pill that treats the skin disease. Sales have ramped up lately, with the therapy churning out $448 million in the fourth quarter to surpass last year’s haul in the same period by more than 20%. And the New Jersey drugmaker is still looking to widen Otezla’s reach: In October, it posted positive phase 3 study results in scalp psoriasis.

Bristol-Myers, meanwhile, wants to upend the market with its own psoriasis newcomer, a fellow oral option currently in phase 3. Last September, the candidate put up stellar phase 2 results, showing it could dramatically reduce symptoms in 12 weeks of treatment.

But the FTC isn’t the only force that could potentially stop the two drugmakers from joining forces. Activist investor Starboard Value has been trying to thwart the mammoth merger by rallying “no” votes from fellow shareholders—such as top stakeholder Wellington Management, which has already come out against the deal. Analysts, though, say for the time being that they still foresee the transaction going through.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.